Author

Na Li

Institutions: F. Hoffmann-La Roche AG, Roche (Canada)

Observed institutions: F. Hoffmann-La Roche AG, Roche (Canada)

OpenAlex ID: A5160022052

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity

2026 · Klara R. Klein, Jeremy Pettus, et al. · Diabetes Care

Works count: 1

Citation count:

H-index:

I10-index: